Laseroptek Co (199550) Fair Value & Analysis
Healthcare · KR · Market cap 39.9B KRW
Fair value as of: Jul 20, 2026
From 1 valuation models · updated 21 days ago
Share price −21.3% over the past month.
Below-average quality, and screening another 66% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (997.35 KRW). The favourable scenario is already priced in.
- Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (526.60 KRW to 997.35 KRW) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
30‑month range 2,255 KRW – 16,234 KRW · fair‑value band 526.60 KRW – 997.35 KRW · the 2,360 KRW price screens above the 797.88 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Laseroptek Co (199550) currently trades at 2,360 KRW, while our model-based Fair Value estimate is 797.88 KRW, implying the stock looks roughly 66.2% overvalued today. The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Laseroptek Co generated revenue of 26.8B KRW at a net margin of -34.3%. Revenue grew 20.8% year over year. It earns a return on equity of -36.2%. Net debt stands at 1.3B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 526.60 KRW (bear case) to 997.35 KRW (bull case); at 2,360 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 72% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -66%, 199550 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 199550 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Laseroptek Co., Ltd. develops and manufactures aesthetic and medical laser devices in South Korea. Its laser devices perform aesthetic and medical dermatological treatments for a range of indications, such as benign pigmentation lesions, fine lines and wrinkles, scar revision, skin rejuvenation and lifting, hair removal, vascular lesions, vitiligo, …
Full company description
Laseroptek Co., Ltd. develops and manufactures aesthetic and medical laser devices in South Korea. Its laser devices perform aesthetic and medical dermatological treatments for a range of indications, such as benign pigmentation lesions, fine lines and wrinkles, scar revision, skin rejuvenation and lifting, hair removal, vascular lesions, vitiligo, psoriasis, atopic dermatitis, leukoderma, and alopecia areata. The company was founded in 2000 and is based in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Laseroptek Co reported revenue of 25.7B KRW in FY2025 versus 18.7B KRW in FY2021, a compound +8.3%/yr. Reported net income was −10.7B KRW in FY2025.
199550 screens 66% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Laseroptek Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Laseroptek Co (199550) overvalued or undervalued?
What is the fair value of 199550?
What is the quality score of 199550?
What is the revenue of Laseroptek Co (199550)?
What is the net profit margin of 199550?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Laseroptek Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.